Skip to main content

Table 3 Multivariate survival analyses

From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

 

DFSª

BCSSb

OSb

 

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

BM3-pos vs. BM3-neg

2.2

1.3-3.9

0.005

2.6

1.4-4.7

0.002

2.6

1.4-4.4

0.002

cN status (vs. N0)

  

0.053

  

0.032

  

0.047

   cN1

2.0

1.0-3.8

0.040

2.3

1.1-4.8

0.019

2.2

1.1-4.3

0.024

   cN 2-4

2.4

1.0-5.6

0.034

2.7

1.1-6.6

0.027

2.4

1.0-5.6

0.049

PgR-pos vs. PgR-neg

1.3

0.7-2.7

0.429

1.8

0.9-3.8

0.118

1.5

0.8-3.1

0.239

ER-pos vs. ER-neg

0.9

0.4-2.0

0.796

1.0

0.5-2.4

0.919

0.9

0.4-2.1

0.897

PB1-pos vs. PB1-neg

   

2.2

0.3-19.1

0.482

2.2

0.3-17.8

0.496

Grade 3 vs.grade 1-2

1.1

0.8-1.5

0.648

1.1

0.6-2.3

0.703

1.3

0.7-2.5

0.482

  1. ªDisease-free survival (DFS) analyzed only in stage M0 patients.
  2. bBreast cancer-free survival (BCSS) and overall survival (OS) analyzed in all patients.
  3. Pos: positive; neg: negative; BM3: bone marrow aspiration pretreatment; cN: clinical node status; PgR: progesterone receptor; ER: estrogen receptor; PB1: peripheral blood sampling pretreatment.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us